FFA
MRNA icon

Farther Finance Advisors’s Moderna MRNA Stock Holding History

Farther Finance Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
15,429
-4,782
-24% -$247K 0.01% 1049
2026
Q1 		$1.01M Buy
20,211
+15,569
+335% +$726K 0.01% 960
2025
Q4 		$137K Buy
4,642
+34
+0.7% +$924 ﹤0.01% 2147
2025
Q3 		$119K Sell
4,608
-175
-4% -$4.88K ﹤0.01% 1932
2025
Q2 		$132K Buy
4,783
+1,238
+35% +$32.6K ﹤0.01% 1608
2025
Q1 		$96.3K Buy
3,545
+26
+0.7% +$923 ﹤0.01% 1561
2024
Q4 		$146K Buy
3,519
+2,615
+289% +$125K 0.01% 1141
2024
Q3 		$60.4K Sell
904
-178
-16% -$16.3K ﹤0.01% 1544
2024
Q2 		$125K Buy
1,082
+271
+33% +$34.3K 0.01% 1036
2024
Q1 		$85.6K Buy
811
+203
+33% +$20.5K 0.01% 994
2023
Q4 		$60.4K Buy
608
+362
+147% +$30.4K ﹤0.01% 980
2023
Q3 		$25.4K Buy
246
+106
+76% +$11.8K ﹤0.01% 1015
2023
Q2 		$17K Buy
140
+26
+23% +$3.47K ﹤0.01% 1047
2023
Q1 		$17.5K Sell
114
-41
-26% -$6.76K 0.01% 942
2022
Q4 		$27.8K Buy
+155
New +$25.3K 0.01% 628

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Farther Finance Advisors's MRNA Position: Q2 2026 in Review

Farther Finance Advisors reduced its Moderna (MRNA) stake by 24% in Q2 2026, selling an estimated $247K and leaving 15,429 shares worth $1.08M. The position accounts for 0.01% of the portfolio, ranked #1049.

Farther Finance Advisors first reported a position in MRNA in Q4 2022 and has held it in 15 quarters since. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Farther Finance Advisors held 15,429 shares of Moderna worth $1.08M as of Q2 2026.
  • Farther Finance Advisors sold 4,782 Moderna shares in Q2 2026, an estimated $247K.
  • Moderna made up 0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #1049 holding.
  • Farther Finance Advisors first reported a position in Moderna in Q4 2022 and has held it in 15 quarters since.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.